These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

377 related items for PubMed ID: 29155868

  • 1. Tocilizumab potentially prevents bone loss in patients with anticitrullinated protein antibody-positive rheumatoid arthritis.
    Chen YM, Chen HH, Huang WN, Liao TL, Chen JP, Chao WC, Lin CT, Hung WT, Hsieh CW, Hsieh TY, Chen YH, Chen DY.
    PLoS One; 2017; 12(11):e0188454. PubMed ID: 29155868
    [Abstract] [Full Text] [Related]

  • 2. The effect of tocilizumab on bone mineral density in patients with methotrexate-resistant active rheumatoid arthritis.
    Kume K, Amano K, Yamada S, Kanazawa T, Ohta H, Hatta K, Amano K, Kuwaba N.
    Rheumatology (Oxford); 2014 May; 53(5):900-3. PubMed ID: 24441151
    [Abstract] [Full Text] [Related]

  • 3. The effect of tocilizumab on bone mineral density, serum levels of Dickkopf-1 and bone remodeling markers in patients with rheumatoid arthritis.
    Briot K, Rouanet S, Schaeverbeke T, Etchepare F, Gaudin P, Perdriger A, Vray M, Steinberg G, Roux C.
    Joint Bone Spine; 2015 Mar; 82(2):109-15. PubMed ID: 25557658
    [Abstract] [Full Text] [Related]

  • 4. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone.
    Garnero P, Thompson E, Woodworth T, Smolen JS.
    Arthritis Rheum; 2010 Jan; 62(1):33-43. PubMed ID: 20039425
    [Abstract] [Full Text] [Related]

  • 5. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss.
    Wijbrandts CA, Klaasen R, Dijkgraaf MG, Gerlag DM, van Eck-Smit BL, Tak PP.
    Ann Rheum Dis; 2009 Mar; 68(3):373-6. PubMed ID: 18408246
    [Abstract] [Full Text] [Related]

  • 6. Periarticular bone gain at proximal interphalangeal joints and changes in bone turnover markers in response to tumor necrosis factor inhibitors in rheumatoid and psoriatic arthritis.
    Szentpetery A, McKenna MJ, Murray BF, Ng CT, Brady JJ, Morrin M, Radovits B, Veale DJ, Fitzgerald O.
    J Rheumatol; 2013 May; 40(5):653-62. PubMed ID: 23457381
    [Abstract] [Full Text] [Related]

  • 7. Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis.
    Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM.
    J Rheumatol; 1997 Aug; 24(8):1489-94. PubMed ID: 9263140
    [Abstract] [Full Text] [Related]

  • 8. Is bone turnover a determinant of bone mass in rheumatoid arthritis?
    Cortet B, Flipo RM, Pigny P, Duquesnoy B, Boersma A, Marchandise X, Delcambre B.
    J Rheumatol; 1998 Dec; 25(12):2339-44. PubMed ID: 9858427
    [Abstract] [Full Text] [Related]

  • 9. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study.
    Lange U, Teichmann J, Müller-Ladner U, Strunk J.
    Rheumatology (Oxford); 2005 Dec; 44(12):1546-8. PubMed ID: 16263785
    [Abstract] [Full Text] [Related]

  • 10. Abatacept might increase bone mineral density at femoral neck for patients with rheumatoid arthritis in clinical practice: AIRTIGHT study.
    Tada M, Inui K, Sugioka Y, Mamoto K, Okano T, Koike T.
    Rheumatol Int; 2018 May; 38(5):777-784. PubMed ID: 29294175
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Titer-Dependent Effect of Anti-Citrullinated Protein Antibodies On Systemic Bone Mass in Rheumatoid Arthritis Patients.
    Orsolini G, Caimmi C, Viapiana O, Idolazzi L, Fracassi E, Gatti D, Adami G, Rossini M.
    Calcif Tissue Int; 2017 Jul; 101(1):17-23. PubMed ID: 28246933
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
    Chopin F, Garnero P, le Henanff A, Debiais F, Daragon A, Roux C, Sany J, Wendling D, Zarnitsky C, Ravaud P, Thomas T.
    Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538
    [Abstract] [Full Text] [Related]

  • 15. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
    Burshell AL, Möricke R, Correa-Rotter R, Chen P, Warner MR, Dalsky GP, Taylor KA, Krege JH.
    Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
    [Abstract] [Full Text] [Related]

  • 16. Changes in bone density and bone turnover in patients with rheumatoid arthritis treated with rituximab, results from an exploratory, prospective study.
    Wheater G, Elshahaly M, Naraghi K, Tuck SP, Datta HK, van Laar JM.
    PLoS One; 2018 Apr; 13(8):e0201527. PubMed ID: 30080871
    [Abstract] [Full Text] [Related]

  • 17. An association between abnormal bone turnover, systemic inflammation, and osteoporosis in patients with chronic pancreatitis: a case-matched study.
    Duggan SN, Purcell C, Kilbane M, O'Keane M, McKenna M, Gaffney P, Ridgway PF, Boran G, Conlon KC.
    Am J Gastroenterol; 2015 Feb; 110(2):336-45. PubMed ID: 25623657
    [Abstract] [Full Text] [Related]

  • 18. Effect of hypercortisolism on bone mineral density and bone metabolism: A potential protective effect of adrenocorticotropic hormone in patients with Cushing's disease.
    Guo W, Li F, Zhu C, Wang B, Wang K, Dai C, Jia H, Wei H, He Q, Cui J, Yuan M, Tang S, Liu W, Zhu T, Gao Z, Zheng F, Ma Z, Qu H, Zhu M.
    J Int Med Res; 2018 Jan; 46(1):492-503. PubMed ID: 28851260
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease.
    Bjøro K, Brandsaeter B, Wiencke K, Bjøro T, Godang K, Bollerslev J, Schrumpf E.
    Scand J Gastroenterol; 2003 Mar; 38(3):320-7. PubMed ID: 12737449
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.